5-MAPB

Not specifically listed in the Controlled Drugs and Substances Act.³ May be considered an analogue of Schedule I amphetamines due to structural relation to MDMA. This legal interpretation has not been tested in court.citation needed

5-MAPB is listed under the 2015 prohibition clause, which took effect on 1 October 2015.

Classified as a narcotic substance since May 9, 2018,¹³ alongside other benzofuran-derived compounds.citation needed

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016.¹⁴ Production, import for market distribution, administration to others, and trading are criminally punishable. Possession is prohibited but not subject to criminal penalty.

5-MAPB is listed as a designated drug (指定薬物) in the ministerial ordinance made under the Pharmaceuticals and Medical Devices Act. The Act prohibits, except for specified medical uses, the manufacture, import, sale, supply, storage or display for sale or supply, advertising, possession, purchase, receipt, and use of designated drugs. The current consolidated ordinance lists 1-(benzofuran-5-yl)-N-methylpropan-2-amine and its salts, the chemical substance known as 5-MAPB.

5-MAPB is prohibited in the Netherlands as a substance within List IA's structural group of substances derived from 2-phenethylamine. The Opiumwet prohibits importing or exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing a substance in a List IA group or a preparation containing it. List IA expressly includes benzofuranyl as a permitted ring system and permits N-alkyl substitution and alkyl substitution on the 2-aminoethyl side chain, which covers 5-(2-methylaminopropyl)benzofuran (5-MAPB).

5-MAPB is listed as a Group I-P psychotropic substance in Poland's national schedule. The regulation has applied since 21 August 2018; unauthorized possession of a psychotropic substance is an offence under Article 62 of the Act on Counteracting Drug Addiction.

Singapore lists N-Methyl-5-(2-aminopropyl)benzofuran (5-MAPB), including its 4-yl, 6-yl and 7-yl isomers, as a Class A drug in the First Schedule to the Misuse of Drugs Act 1973. It is therefore a controlled drug; the Act prohibits trafficking, possession, import or export, and manufacture except as authorised under the Act.

Initially placed under a Temporary Class Drug order in June 2013 following ACMD recommendation.³¹³² Permanently classified as a Class B, Schedule 1 substance on June 10, 2014,³³ alongside all other benzofuran entactogens and structurally related compounds.

The exact 5-MAPB listing is current in the 1130/2014 annex, whose consolidated Finlex metadata is dated 25 June 2026 and records the latest amendment (650/2026) effective 10 July 2026. The substance is 5-(N-metyyli-2-aminopropyyli)bentsofuraani, with the parenthetical chemical name 1-(1-bentsofuran-5-yyli)-N-metyylipropaani-2-amiini; the annex also extends its list to chemically possible stereoisomers and salts unless specifically excluded. Under Narcotics Act § 5(2), manufacture, import into Finland, storage, offering for sale and transfer of a consumer-market-banned psychoactive substance are prohibited, subject to the research, justified industrial and low-misuse-risk preparation routes in § 23b. Section 44:5a of the Criminal Code makes intentional or grossly negligent violation of those conduct prohibitions punishable by a fine or imprisonment for up to one year, unless a more serious offence applies. The Finnish provisions do not state a blanket possession-or-use prohibition for this distinct consumer-market category. The current 543/2008 narcotics schedules expressly show 5-APB and 6-APB in Annex IV but no 5-MAPB occurrence; 5-MAPB is distinct from the separately scheduled narcotic 5-APB, and the schedules do not establish narcotic analogue liability.

5-MAPB is listed as a health-hazardous good under the Ordinance (1999:58) on the prohibition of certain health-hazardous goods. The Act (1999:42) prohibits, without authorization, its importation, transfer, manufacture, acquisition for transfer, sale offer, and possession, and prohibits other handling not intended for personal use.

5-MAPB is listed in BetmVV-EDI, the legally binding schedule source.

Not specifically scheduled under federal law. However, due to structural similarity to MDA and MDMA, sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act,³⁴ though no such cases are known.citation needed

The official Legilux consolidation is expressly applicable from 13 July 2026. Article 1 subjects substances enumerated in the annex to Article 7 of the 1973 law and extends that treatment to their stereoisomers, specified naturally containing organisms and reproductive biological material; it does not state a general chemical-analogue rule. 5-MAPB is not an isomer of a listed substance and is absent from the annex. Under this instrument, 5-MAPB is unscheduled. The Police's current public summary gives general maximum penalties for 'other drugs' only where the drug is otherwise controlled; it does not specify a penalty for 5-MAPB.